These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 8164028

  • 21. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
    Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF.
    Cancer; 1997 Mar 15; 79(6):1216-24. PubMed ID: 9070501
    [Abstract] [Full Text] [Related]

  • 22. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
    Danner K, Becker HG, Best B, Madler C.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul 15; 36(7):425-30. PubMed ID: 11496617
    [Abstract] [Full Text] [Related]

  • 23. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers.
    Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF.
    J Clin Pharmacol; 1995 Jul 15; 35(7):705-12. PubMed ID: 7560251
    [Abstract] [Full Text] [Related]

  • 24. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 25. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
    Diemunsch P, Leeser J, Feiss P, D'Hollander A, Bradburn BG, Paxton D, Whitmore J, Panouillot P, Navé S, Brown RA, Hahne WF.
    Can J Anaesth; 1997 Feb 01; 44(2):173-81. PubMed ID: 9043731
    [Abstract] [Full Text] [Related]

  • 26. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M, Xu R, Seth R.
    Curr Med Res Opin; 2004 Jun 01; 20(6):879-82. PubMed ID: 15200746
    [Abstract] [Full Text] [Related]

  • 27. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Proto E, Santona MC.
    Cancer; 1996 Mar 01; 77(5):941-8. PubMed ID: 8608488
    [Abstract] [Full Text] [Related]

  • 28. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
    Merrouche Y, Catimel G, Rebattu P, Dumortier A, Guastalla JP, O'Grady P, Clavel M.
    Ann Oncol; 1994 Jul 01; 5(6):549-51. PubMed ID: 7918128
    [Abstract] [Full Text] [Related]

  • 29. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG, Tyson LB, Clark RA, Gralla RJ.
    Cancer; 1992 Aug 15; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [Abstract] [Full Text] [Related]

  • 30. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
    Kovac AL, Scuderi PE, Boerner TF, Chelly JE, Goldberg ME, Hantler CB, Hahne WF, Brown RA.
    Anesth Analg; 1997 Sep 15; 85(3):546-52. PubMed ID: 9296407
    [Abstract] [Full Text] [Related]

  • 31. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG.
    Semin Oncol; 1994 Oct 15; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [Abstract] [Full Text] [Related]

  • 32. Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Kirchner V, Aapro M, Alberto P, O'Grady P, Busch B, Boyce M.
    Ann Oncol; 1993 Jun 15; 4(6):481-4. PubMed ID: 8353090
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.
    Warriner CB, Knox D, Belo S, Cole C, Finegan BA, Perreault L.
    Can J Anaesth; 1997 Nov 15; 44(11):1167-73. PubMed ID: 9398956
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.